Efferon's Pediatric Sepsis Device Lands CE Mark and $2M Revenue Path

Sepsis kills roughly 3 million children under the age of five every year, and a startup called Efferon has just built the first multimodal blood purification device engineered specifically to cut that toll in pediatric intensive care.

In April, Efferon's pediatric device, Efferon NEO, received a CE mark — Europe's equivalent of FDA approval — making it the first multimodal blood purification device designed specifically for pediatric sepsis. The company is now preparing to file for FDA approval in the United States.

Efferon was selected as one of TechCrunch Disrupt 2026's Startup Battlefield 200, and it arrives at the competition with a commercial footprint already in place: Efferon NEO is used in intensive care units across 30 countries, including European hospitals, Saudi Arabia, and Thailand. The company is on track to hit $2 million in annualized revenue by the end of 2026.

What does the device actually do?

Sepsis is an acute inflammation triggered by infection and ranks among the leading causes of childhood mortality. When standard treatments like antibiotics cannot stop the immune system's overreaction, a patient's blood must be filtered to remove deadly toxins. Efferon's absorbers are built to capture dangerous cytokines and toxins during that filtration.

Dima Romashin, Efferon's co-founder and CEO, compares what happens in the body during sepsis to a fire that overwhelms the building rapidly. "In a fire, there are two things: the flame itself and smoke that it produces," he told TechCrunch.

In sepsis, endotoxins are the flames and cytokines are the smoke. Efferon, unlike other devices on the market, has developed a mechanism that can absorb both at once, according to Romashin. The company says its devices lower organ failure rates and significantly accelerate recovery in children.

Why a separate device for children?

Efferon also makes absorbers for adults, but Efferon NEO is proving especially effective in young patients. The reason is physiological: children have a significantly lower circulating blood volume, so they require medical devices engineered specifically for their bodies rather than scaled-down adult equipment, according to Romashin.

That design constraint is what separates Efferon NEO from general-purpose blood purification hardware already installed in ICUs — and what earned it the CE mark as a first-in-class pediatric device.

Who is behind the company?

The startup's technology was originally developed by scientists at Moscow State University, including co-founder Ivan Bessonov. Romashin, a serial entrepreneur, recognized its potential and stepped in earlier this year as CEO to help commercialize it.

That division of labor is deliberate. The science came from the university lab; the go-to-market engine came from an operator who has built companies before. The commercialization push has already produced results in two regulatory and commercial milestones — the CE mark in April and the 30-country footprint — within a single year.

How does Efferon measure success?

Romashin admits that Efferon isn't growing at the breakneck pace of today's AI startups. True success for the company is measured by something else entirely: every child who gets to go home.

With an FDA filing in preparation and $2 million in annualized revenue targeted by the end of 2026, Efferon's next test is whether a device built for a niche but lethal condition can scale in the world's largest healthcare market — and whether the dual-absorption approach can move the numbers on a disease that claims millions of young lives annually.